A clinical trial conducted by the World Health Organization found that Gilead Sciences Inc.'s remdesivir, hydroxychloroquine, AbbVie's undefined lopinavir/ritonavir and interferon did not impact mortality among hospitalized COVID-19 patients. The study was first reported by the Financial Times on Thursday. In a preprint, which is medical research that has not been peer-reviewed, researchers said that the four antiviral drugs had
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
World caught in 'syndemic' of chronic diseases and COVID-19, global study saysThe world is caught in a perfect storm of rising rates of chronic disease, persistent infectious diseases and public health failures that have fuelled deaths in the COVID-19 pandemic, according to a major global study of human health.
Read more »
Eli Lilly says other COVID-19 antibody drug trials ongoing after study halted for safety concernEli Lilly & Co on Wednesday said other trials of its experimental coronavirus antibody therapy remain on track after a government-run study testing the treatment in hospitalized COVID-19 patients was paused due to safety concerns.
Read more »
Day-Care Centers Are Very Low Risk for Covid-19 Transmission, Study SaysChildren in day-care programs present virtually no risk of transmitting Covid-19 to adults, according to a new Yale University study of more than 57,000 U.S. child-care providers.
Read more »
Child care programs not associated with COVID-19 spread, large study findsA recent study surveyed 57,000 child care providers and found that there was no 'heightened risk' of coronavirus transmission if safety practices were followed.
Read more »
Working in child care does not elevate risk of getting Covid-19, Yale study findsWorking in child care does not increase the likelihood of adults contracting Covid-19, according to a new academic study from Yale University published Wednesday.
Read more »